<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35585556</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1745-6215</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>May</Month><Day>18</Day></PubDate></JournalIssue><Title>Trials</Title><ISOAbbreviation>Trials</ISOAbbreviation></Journal><ArticleTitle>Efficacy and safety of Lenzumestrocel (Neuronata-R&#xae; inj.) in patients with amyotrophic lateral sclerosis (ALSUMMIT study): study protocol for a multicentre, randomized, double-blind, parallel-group, sham procedure-controlled, phase III trial.</ArticleTitle><Pagination><StartPage>415</StartPage><MedlinePgn>415</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">415</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-022-06327-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A single cycle (two repeated treatments) with intrathecal autologous bone marrow-derived mesenchymal stem cells (BM-MSCs, 26-day interval) showed safety and provided therapeutic benefit lasting 6 months in patients with ALS but did not demonstrate long-term efficacy. This phase III clinical trial (ALSUMMIT) protocol was developed to evaluate the long-term efficacy and safety of the combined protocol of single-cycle intrathecal therapy and three additional booster injections of BM-MSC (Lenzumestrocel) treatment in patients with ALS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">ALSUMMIT is a multicentre, randomized, double-blind, parallel-group, sham procedure-controlled, phase III trial for ALS. The 115 subjects will be randomized (1:2:2) into three groups: (1) study Group 1 (single-cycle, two repeated injections with 26-day interval), (2) study Group 2 (single-cycle + three additional booster injections at 4, 7, and 10 months), and (3) the control group. Participants who have an intermediate rate of disease progression will be included in this trial to reduce clinical heterogeneity. The primary endpoint will be evaluated by combined assessment of function and survival (CAFS), also known as joint rank scores (JRS), at 6 months (study Group 1 vs. control) and 12 months (study Group 2 vs. control) after the first Lenzumestrocel or placebo administration. Safety assessment will be performed throughout the study period. Additionally, after the 56-week main study, a long-term follow-up observational study will be conducted to evaluate the long-term efficacy and safety up to 36 months.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Lenzumestrocel is the orphan cell therapy product for ALS conditionally approved by the South Korea Ministry of Food and Drug Safety (MFDS). This ALSUMMIT protocol was developed for the adoption of enrichment enrolment, add-on design, and consideration of ethical issues for the placebo group.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov NCT04745299 . Registered on Feb 9, 2021. Clinical Research Information Service (CRIS) KCT0005954 . Registered on Mar 4, 2021.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Nam</LastName><ForeName>Jae-Yong</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Central Research Center, Corestem Inc, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lee</LastName><ForeName>Tae Yong</ForeName><Initials>TY</Initials><AffiliationInfo><Affiliation>Central Research Center, Corestem Inc, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Pharmacy, Chungbuk National University, Cheongju, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Kwijoo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Central Research Center, Corestem Inc, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chun</LastName><ForeName>Sehwan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Central Research Center, Corestem Inc, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Min Sung</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Central Research Center, Corestem Inc, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Pharmacy, Chungbuk National University, Cheongju, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Jin-Hong</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Pusan National University, Yangsan, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sung</LastName><ForeName>Jung-Joon</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Seoul National University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Byoung Joon</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Samsung Medical Center, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Byung-Jo</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Korea University Anam Hospital, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Ki-Wook</ForeName><Initials>KW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hanyang University Hospital, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Kyung Suk</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Central Research Center, Corestem Inc, Seoul, South Korea. kskim@corestem.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seung Hyun</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hanyang University Hospital, Seoul, South Korea. kimsh1@hanyang.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04745299</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trials</MedlineTA><NlmUniqueID>101263253</NlmUniqueID><ISSNLinking>1745-6215</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064987" MajorTopicYN="N">Cell- and Tissue-Based Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017326" MajorTopicYN="N">Clinical Trials, Phase III as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059630" MajorTopicYN="Y">Mesenchymal Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Bone marrow-derived mesenchymal stem cell</Keyword><Keyword MajorTopicYN="N">Lenzumestrocel</Keyword><Keyword MajorTopicYN="N">Phase III</Keyword></KeywordList><CoiStatement>JYN, TYL, KJK, SHC, MSK, and KSK are employees of Corestem Inc. All other authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>18</Day><Hour>23</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35585556</ArticleId><ArticleId IdType="pmc">PMC9115933</ArticleId><ArticleId IdType="doi">10.1186/s13063-022-06327-4</ArticleId><ArticleId IdType="pii">10.1186/s13063-022-06327-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR, Zoing MC. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942&#x2013;955. doi: 10.1016/S0140-6736(10)61156-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Diagnosis ETFo. Management of Amyotrophic Lateral S. Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, Hardiman O, Kollewe K, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force. Eur J Neurol. 2012;19(3):360&#x2013;375. doi: 10.1111/j.1468-1331.2011.03501.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2011.03501.x</ArticleId><ArticleId IdType="pubmed">21914052</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;(3):CD001447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055506</ArticleId><ArticleId IdType="pubmed">22419278</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD. Edaravone: A new drug approved for ALS. Cell. 2017;171(4):725. doi: 10.1016/j.cell.2017.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.10.011</ArticleId><ArticleId IdType="pubmed">29100067</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA. ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Front Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Riboldi G, Zanetta C, Ranieri M, Nizzardo M, Simone C, Magri F, Bresolin N, Comi GP, Corti S. Antisense oligonucleotide therapy for the treatment of C9ORF72 ALS/FTD diseases. Mol Neurobiol. 2014;50(3):721&#x2013;732. doi: 10.1007/s12035-014-8724-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-014-8724-7</ArticleId><ArticleId IdType="pubmed">24809691</ArticleId></ArticleIdList></Reference><Reference><Citation>van Zundert B, Brown RH., Jr Silencing strategies for therapy of SOD1-mediated ALS. Neurosci Lett. 2017;636:32&#x2013;39. doi: 10.1016/j.neulet.2016.07.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2016.07.059</ArticleId><ArticleId IdType="pubmed">27507699</ArticleId></ArticleIdList></Reference><Reference><Citation>Blair IP, Williams KL, Warraich ST, Durnall JC, Thoeng AD, Manavis J, Blumbergs PC, Vucic S, Kiernan MC, Nicholson GA. FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. J Neurol Neurosurg Psychiatry. 2010;81(6):639&#x2013;645. doi: 10.1136/jnnp.2009.194399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.194399</ArticleId><ArticleId IdType="pubmed">19965854</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabatelli M, Conte A, Zollino M. Clinical and genetic heterogeneity of amyotrophic lateral sclerosis. Clin Genet. 2013;83(5):408&#x2013;416. doi: 10.1111/cge.12117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cge.12117</ArticleId><ArticleId IdType="pubmed">23379621</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis CM, Suzuki M. Therapeutic applications of mesenchymal stem cells for amyotrophic lateral sclerosis. Stem Cell Res Ther. 2014;5(2):32. doi: 10.1186/scrt421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/scrt421</ArticleId><ArticleId IdType="pmc">PMC4035799</ArticleId><ArticleId IdType="pubmed">25157751</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang BL. The use of mesenchymal stem cells (MSCs) for amyotrophic lateral sclerosis (ALS) therapy - a perspective on cell biological mechanisms. Rev Neurosci. 2017;28(7):725&#x2013;738. doi: 10.1515/revneuro-2017-0018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/revneuro-2017-0018</ArticleId><ArticleId IdType="pubmed">28599400</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon MS, Noh MY, Oh KW, Cho KA, Kang BY, Kim KS, Kim YS, Kim SH. The immunomodulatory effects of human mesenchymal stem cells on peripheral blood mononuclear cells in ALS patients. J Neurochem. 2014;131(2):206&#x2013;218. doi: 10.1111/jnc.12814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.12814</ArticleId><ArticleId IdType="pubmed">24995608</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13(4):392&#x2013;402. doi: 10.1016/j.stem.2013.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2013.09.006</ArticleId><ArticleId IdType="pubmed">24094322</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh KW, Noh MY, Kwon MS, Kim HY, Oh SI, Park J, Kim HJ, Ki CS, Kim SH. Repeated Intrathecal Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis. Ann Neurol. 2018;84(3):361&#x2013;373. doi: 10.1002/ana.25302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25302</ArticleId><ArticleId IdType="pmc">PMC6175096</ArticleId><ArticleId IdType="pubmed">30048006</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci. 1994;124(Suppl):96&#x2013;107. doi: 10.1016/0022-510X(94)90191-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(94)90191-0</ArticleId><ArticleId IdType="pubmed">7807156</ArticleId></ArticleIdList></Reference><Reference><Citation>Teeple E, Scott DL, Ghia JN. Intrathecal normal saline without preservative does not have a local anesthetic effect. Pain. 1982;14(1):3&#x2013;10. doi: 10.1016/0304-3959(82)90075-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-3959(82)90075-6</ArticleId><ArticleId IdType="pubmed">6897288</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315&#x2013;317. doi: 10.1080/14653240600855905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14653240600855905</ArticleId><ArticleId IdType="pubmed">16923606</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry JD, Miller R, Moore DH, Cudkowicz ME, van den Berg LH, Kerr DA, Dong Y, Ingersoll EW, Archibald D. The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(3):162&#x2013;168. doi: 10.3109/21678421.2012.762930.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2012.762930</ArticleId><ArticleId IdType="pubmed">23323713</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh KW, Moon C, Kim HY, Oh SI, Park J, Lee JH, Chang IY, Kim KS, Kim SH. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis. Stem Cells Transl Med. 2015;4(6):590&#x2013;597. doi: 10.5966/sctm.2014-0212.</Citation><ArticleIdList><ArticleId IdType="doi">10.5966/sctm.2014-0212</ArticleId><ArticleId IdType="pmc">PMC4449093</ArticleId><ArticleId IdType="pubmed">25934946</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdul Wahid SF, Law ZK, Ismail NA, Lai NM. Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2019;12(CD011742).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6920743</ArticleId><ArticleId IdType="pubmed">31853962</ArticleId></ArticleIdList></Reference><Reference><Citation>Galpern WR, Corrigan-Curay J, Lang AE, Kahn J, Tagle D, Barker RA, Freeman TB, Goetz CG, Kieburtz K, Kim SY, et al. Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurol. 2012;11(7):643&#x2013;650. doi: 10.1016/S1474-4422(12)70064-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70064-9</ArticleId><ArticleId IdType="pubmed">22710757</ArticleId></ArticleIdList></Reference><Reference><Citation>Amyotrophic Lateral Sclerosis: Developing Drugs for Treatment. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/amyotrophic-lateral-sclerosis-developing-drugs-treatment-guidance-industry.</Citation></Reference><Reference><Citation>Goyal NA, Berry JD, Windebank A, Staff NP, Maragakis NJ, van den Berg LH, Genge A, Miller R, Baloh RH, Kern R, et al. Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS. Muscle Nerve. 2020;62(2):156&#x2013;166. doi: 10.1002/mus.26801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26801</ArticleId><ArticleId IdType="pmc">PMC7496557</ArticleId><ArticleId IdType="pubmed">31899540</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>